Format

Send to

Choose Destination
J Immunother. 2013 Nov-Dec;36(9):490-5. doi: 10.1097/CJI.0000000000000003.

A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study.

Author information

1
*Dartmouth Hitchcock Medical Center, Lebanon, NH †Dana-Farber Cancer Institute, Harvard School of Public Health ∥Beth Israel Deaconess Medical Center ‡‡Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA ‡Vanderbilt University Medical Center, Nashville, TN §Loyola University Medical Center, Maywood, IL ¶Georgetown Lombardi Comprehensive Cancer Center, Washington, DC #St. Luke's Roosevelt Hospital Center, New York, NY **Earle A. Chiles Research Institute ††Providence Cancer Center, Portland, OR §§Department of Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI ∥∥Division of Oncology, Department of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, WA.

Abstract

Overexpression of vascular endothelial growth factor in renal cell carcinoma (RCC) leads to angiogenesis, tumor progression, and inhibition of immune function. We conducted the first phase II study to estimate the efficacy and safety of bevacizumab with high-dose interleukin-2 (IL-2) therapy in patients with metastatic RCC. Eligible patients had predominantly clear cell metastatic RCC, measurable disease, a Karnofsky Performance Status of ≥80%, and adequate end-organ function. IL-2 (600,000 IU/kg) was infused intravenously every 8 hours (maximum 28 doses) during two 5-day cycles on days 1 and 15 of each 84-day course. Bevacizumab (10 mg/kg) was infused intravenously every 2 weeks beginning 2 weeks before initiating IL-2. Fifty of 51 eligible patients from 8 centers were enrolled. Median progression-free survival (PFS) was 11.2 months (90% confidence interval, 5.7-17.7), and 2-year PFS was 18% (90% confidence interval, 8%-27%). Responses included 4 complete (8%) and 11 partial (22%) responses. Toxicities did not exceed those expected from each agent alone. Combining IL-2 plus bevacizumab is feasible, with a response rate and PFS at least as high as reported previously for the single agents. The regimen did not appear to enhance the rate of durable major responses over that of IL-2 alone.

PMID:
24145360
DOI:
10.1097/CJI.0000000000000003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center